Zydus begins supply of ZyCoV-D to center

Zydus Cadila, a pharmaceutical company, said on February 2 that it has begun supplying the Central Government with its COVID-19 vaccine ZyCoV-D.

The company has begun supplying in response to the government’s directive, according to a statement from the pharmaceutical company.

The organisation also intends to make the vaccine available on the private market, according to the statement.

“The vaccine will be priced at ₹265 per dose and the applicator being offered at ₹93 per dose, excluding GST,” Zydus Cadila said.

The Ahmedabad-based drugmaker has also entered into a definitive agreement with Shilpa Medicare Ltd., a contract manufacturing organisation, to produce mutually agreeable doses of ZyCoV-D.

It has also entered into an agreement with Enzychem Lifesciences of the Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine, Zydus Cadila noted.

ZyCoV-D is a Plasmid DNA vaccine that produces the spike protein of the SARS-CoV-2 virus and elicits an immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance.